Innate and adaptive immune responses toward nanomedicines.

Viana, Iara Maíra de Oliveira; Roussel, Sabrina; Defrêne, Joan; Lima, Eliana Martins; Barabé, Frédéric; Bertrand, Nicolas

Viana, Iara Maíra de Oliveira; Roussel, Sabrina; Defrêne, Joan; Lima, Eliana Martins; Barabé, Frédéric; Bertrand, Nicolas.

Afiliação

Viana IMO; Laboratory of Pharmaceutical Technology (FarmaTec), Federal University of Goiás, Goiânia 74605-220, Brazil.
Roussel S; Faculty of Pharmacy, Université Laval and CHU de Québec-Université Laval Research Center, Québec G1V 4G2, Canada.
Defrêne J; Faculty of Pharmacy, Université Laval and CHU de Québec-Université Laval Research Center, Québec G1V 4G2, Canada.
Lima EM; Department of Medicine, Faculty of Medicine, Université Laval and CHU de Québec-Université Laval Research Center, Québec G1V 4G2, Canada.
Barabé F; Laboratory of Pharmaceutical Technology (FarmaTec), Federal University of Goiás, Goiânia 74605-220, Brazil.
Bertrand N; Department of Medicine, Faculty of Medicine, Université Laval and CHU de Québec-Université Laval Research Center, Québec G1V 4G2, Canada.

Acta Pharm Sin B ; 11(4): 852-870, 2021 Apr.

Article em En | MEDLINE | ID: mdl-33747756

Palavras-chave

Anti-PEG antibody; BNT162b2; Cancer immunotherapy; Complement activation; Immunology; In vivo clearance; Macrophage; Nanoparticle; mRNA vaccine; mRNA-1273

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Acta Pharm Sin B Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google